NEJM:低风险未经产妇引产与待产比较

2018-08-09 xing.T MedSci原创

由此可见,在低风险的未经产妇女中妊娠39周引产并未导致复合性不良围产期结局发生频率的显著降低,但确实可以显著降低剖宫产率。

在低风险的未经产妇女中,39周引产的围产期和产妇结局尚未明确。近日,顶级医学期刊NEJM上针对这一问题发表了一篇研究文章。

在这项多中心试验中,研究人员随机分配了妊娠38周0天至38周6天的低风险未生育女性在39周0天至39周4天内进行分娩诱导或待产管理。该研究的主要结局是围产期死亡或严重新生儿并发症复合事件;主要的次要结局为剖腹产。

该研究共有3062名妇女被分配进行引产,3044名妇女被分配到进行待产管理。主要结果发生在引产组中4.3%的新生儿和待产管理组中5.4%的新生儿(相对风险为0.80; 95%置信区间[CI]为0.64-1.00)。引产组的剖宫产率显著低于待产治疗组(18.6% vs. 22.2%;相对风险为0.84; 95%CI为0.76-0.93)。

由此可见,在低风险的未经产妇女中妊娠39周引产并未导致复合性不良围产期结局发生频率的显著降低,但确实可以显著降低剖宫产率。

原始出处:

William A. Grobman,et al. Labor Induction versus Expectant Management in Low-Risk Nulliparous Women. N Engl J Med 2018; https://www.nejm.org/doi/full/10.1056/NEJMoa1800566

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=339364, encodeId=1b0a33936424, content=不错耶,学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Aug 18 15:45:10 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574052, encodeId=6f9d15e405214, content=<a href='/topic/show?id=60244986058' target=_blank style='color:#2F92EE;'>#引产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49860, encryptionId=60244986058, topicName=引产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cb015981848, createdName=cmsvly, createdTime=Fri Aug 10 23:54:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337532, encodeId=7ebe33e532c0, content=我就, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Thu Aug 09 12:29:12 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337519, encodeId=59a733e519dc, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 09 11:00:14 CST 2018, time=2018-08-09, status=1, ipAttribution=)]
    2018-08-18 owlhealth

    不错耶,学习啦

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=339364, encodeId=1b0a33936424, content=不错耶,学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Aug 18 15:45:10 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574052, encodeId=6f9d15e405214, content=<a href='/topic/show?id=60244986058' target=_blank style='color:#2F92EE;'>#引产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49860, encryptionId=60244986058, topicName=引产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cb015981848, createdName=cmsvly, createdTime=Fri Aug 10 23:54:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337532, encodeId=7ebe33e532c0, content=我就, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Thu Aug 09 12:29:12 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337519, encodeId=59a733e519dc, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 09 11:00:14 CST 2018, time=2018-08-09, status=1, ipAttribution=)]
    2018-08-10 cmsvly
  3. [GetPortalCommentsPageByObjectIdResponse(id=339364, encodeId=1b0a33936424, content=不错耶,学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Aug 18 15:45:10 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574052, encodeId=6f9d15e405214, content=<a href='/topic/show?id=60244986058' target=_blank style='color:#2F92EE;'>#引产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49860, encryptionId=60244986058, topicName=引产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cb015981848, createdName=cmsvly, createdTime=Fri Aug 10 23:54:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337532, encodeId=7ebe33e532c0, content=我就, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Thu Aug 09 12:29:12 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337519, encodeId=59a733e519dc, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 09 11:00:14 CST 2018, time=2018-08-09, status=1, ipAttribution=)]
    2018-08-09 哈哈869

    我就

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=339364, encodeId=1b0a33936424, content=不错耶,学习啦, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Sat Aug 18 15:45:10 CST 2018, time=2018-08-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1574052, encodeId=6f9d15e405214, content=<a href='/topic/show?id=60244986058' target=_blank style='color:#2F92EE;'>#引产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49860, encryptionId=60244986058, topicName=引产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0cb015981848, createdName=cmsvly, createdTime=Fri Aug 10 23:54:00 CST 2018, time=2018-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337532, encodeId=7ebe33e532c0, content=我就, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKcmgibQ4oCrK7Z6f4CvMcs4k7QUGCkhopcGxvxaBfVciadECSIwaRVttllIOEKumpEaRrq5PoOUxow/0, createdBy=e3bb2081203, createdName=哈哈869, createdTime=Thu Aug 09 12:29:12 CST 2018, time=2018-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337519, encodeId=59a733e519dc, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Thu Aug 09 11:00:14 CST 2018, time=2018-08-09, status=1, ipAttribution=)]
    2018-08-09 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

相关资讯

Lancet Gastroenterology & Hepatology:低风险消化道出血患者识别方法

研究人员开发了一种新的临床预测模型用于下消化道出血患者风险评估,该系统对患者的合理化治疗以及医疗资源节约具有重要意义

JAHA:心血管低风险人群24小时中心脉压对心血管事件的预测分析!

由此可见。24小时中心脉压能改善心血管低风险高血压患者的心血管事件预测。

Arch Ital Urol Androl:低风险前列前癌冷冻疗法的肿瘤学和功能的中期结果

最近,研究人员分析了受低风险前列腺癌影响的并经历前列腺冷冻治疗的病人的肿瘤学和功能结果情况。设计的研究是一个前瞻性的三个中心点的研究,包括了434名患有低风险前列腺癌且经历前列腺冷冻疗法的病人。另外,研究人员通过参考 D'Amico的风险分层进行低风险确定,还根据Onik描述的技术对每一位病人进行了两轮的冻融。研究发现,434名病人的平均年龄为66岁,标准差为±6.68;平均的PSA为6.17ng

BMC Med Research Method:进行低风险临床试验前,患者对知情同意书的态度如何?

知情同意书(Information Consent Form, ICF)是保护受试者个体权益的重要武器,它既规范临床医疗行为,又约束研究行为的伦理原则。

CCR:积极监测有利于低风险前列腺癌患者

    《临床癌症研究》9月24日在线发表的一项研究报告显示,与立即接受根治性前列腺切除术相比,行积极监测的低风险前列腺癌男性患者癌症特异性生存期减少“甚微”,仅1.8个月。然而,后者可少受6年多的治疗以及由此导致的不良反应痛苦(Clin. Cancer Res. 2012 Sept. 24 [doi:10.1158/1078-0432.CCR-12-1502])。